Posts Feed
Comments Feed

Archive for the 'Dermatology' Category

Arpida Publishes Top-Line Data Of Phase II “Intravenous-To-Oral” Switch Trial With Oral Iclaprim

Jan 3rd 2009Drug InformationDermatology

Arpida Ltd. (SWX: ARPN) announces positive top-line data of the Phase II ‘intravenous-to-oral’ switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI). The top-line results demonstrated high clinical cure rates of over 90% following the step-down therapy with oral iclaprim administered after two days of initial treatment with intravenous vancomycin.

More: continued here

No Comments »

Chorionic Villus Sampling May Increase Risk Of Hemangiomas

Jan 3rd 2009Drug InformationDermatology

Performing chorionic villus sampling (CVS) for prenatal diagnosis may lead to an increased rate of blood vessel malformations called hemangiomas in infants, according to a review in the November Journal of Craniofacial Surgery.

More: continued here

No Comments »

EpiDerm’s Skin Irritation Test Fully Validated In European Union

Dec 19th 2008Drug InformationDermatology

MatTek Corporation announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the scientific validity of the Modified EpiDerm Skin Irritation Test (SIT) at its November meeting. ESAC concluded that the Modified EpiDerm SIT has sufficient accuracy and reliability for the prediction of skin irritating and non-irritating test substances. The Updated EpiDerm SIT is a modification of the previously validated EpiDerm skin irritation method (ESAC Statement, April 2007).

More: continued here

No Comments »

« Prev - Next »

1